Literature DB >> 22616719

The leukotriene receptor antagonist montelukast and aortic stenosis.

Magnus Bäck, Li Yin, Edit Nagy, Erik Ingelsson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22616719      PMCID: PMC3555071          DOI: 10.1111/j.1365-2125.2012.04338.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  4 in total

1.  Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.

Authors:  Magnus Bäck; Li Yin; Erik Ingelsson
Journal:  Eur Heart J       Date:  2011-11-21       Impact factor: 29.983

Review 2.  Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update.

Authors:  Nalini M Rajamannan; Frank J Evans; Elena Aikawa; K Jane Grande-Allen; Linda L Demer; Donald D Heistad; Craig A Simmons; Kristyn S Masters; Patrick Mathieu; Kevin D O'Brien; Frederick J Schoen; Dwight A Towler; Ajit P Yoganathan; Catherine M Otto
Journal:  Circulation       Date:  2011-10-18       Impact factor: 29.690

3.  Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease.

Authors:  Erik Ingelsson; Li Yin; Magnus Bäck
Journal:  J Allergy Clin Immunol       Date:  2012-01-12       Impact factor: 10.793

4.  Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts.

Authors:  Edit Nagy; Daniel C Andersson; Kenneth Caidahl; Maria J Eriksson; Per Eriksson; Anders Franco-Cereceda; Göran K Hansson; Magnus Bäck
Journal:  Circulation       Date:  2011-03-14       Impact factor: 29.690

  4 in total
  1 in total

1.  Montelukast attenuates interleukin IL-1β-induced oxidative stress and apoptosis in chondrocytes by inhibiting CYSLTR1 (Cysteinyl Leukotriene Receptor 1) and activating KLF2 (Kruppel Like Factor 2).

Authors:  Zongwei Li; Jianming Wang; Yumin Ma
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.